Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AL002 · 2 trials · 2 indications
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) score at Weeks 24, 48, 72 and 96. The CDR-SB is a tool used to measure disease severity in Alzheimer's disease. This scale assesses three domains of cognition and three domains of function. The domains are rated on a 5 point scale in which the higher the score corresponds to greater cognitive impairment. The scale range is from 0 to 18 where 0 is considered normal and 18 indicates severe dementia.
Incidence of adverse events and dose limiting Adverse Events during the DLAE observation period and/or study treatment periods.
| Arm | Type | Description |
|---|---|---|
| AL002 Dose 1 | EXPERIMENTAL | AL002 every 4 weeks |
| AL002 Dose 2 | EXPERIMENTAL | AL002 every 4 weeks |
| AL002 Dose 3 | EXPERIMENTAL | AL002 every 4 weeks |
| Placebo | PLACEBO_COMPARATOR | Placebo every 4 weeks |
| AL002 | ACTIVE_COMPARATOR | AL002 by intravenous (IV) infusion |
| Saline Solution | PLACEBO_COMPARATOR | placebo by intravenous (IV) infusion |
| Name | Type | Description |
|---|---|---|
| AL002 | DRUG | Administered via intravenous (IV) infusion |
| Placebo | DRUG | Administered via intravenous (IV) infusion |
| Saline Solution | OTHER | Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects for HV and 10 active and 2 placebo for patients |
Inclusion Criteria: * Diagnosis of Early AD including evidence of brain amyloidosis by CSF or PET * MMSE score ≥ 20 points, CDR Global Score of 0.5 - 1.0, and RBANS score on the DMI ≤95. * Study partner who consents to study participation and who cares for/visits the participant at least 10 hours a...
Top 20 of 24 competitors
AL002 is an investigational small molecule being studied for the treatment of Alzheimer's disease. It has been evaluated in clinical trials involving participants with early Alzheimer's disease, as well as in healthy volunteers. The drug is being developed by Alector, Inc. and is currently in Phase 2 clinical development.
AL002 is a small molecule developed by Alector, Inc. for the treatment of Alzheimer's disease. The specific molecular target of AL002 has not been disclosed in available clinical trial information. The drug is being investigated for its potential to modify the course of early Alzheimer's disease.
AL002 is being developed by Alector, Inc., a biopharmaceutical company focused on immunology and neurology. Alector is publicly traded under the ticker symbol ALEC. The company is conducting clinical trials to evaluate AL002 as a potential treatment for Alzheimer's disease.
AL002 is currently in Phase 2 clinical development for the treatment of early Alzheimer's disease. A Phase 2 study has been completed, evaluating the efficacy and safety of AL002 in participants with early Alzheimer's disease. The drug is investigational and has not been approved by regulatory authorities.
AL002 has been studied in two clinical trials. A Phase 1 study (NCT03635047) assessed safety and tolerability in healthy volunteers and participants with Alzheimer's disease. A Phase 2 study (NCT04592874) evaluated efficacy and safety in 356 participants with early Alzheimer's disease. Both trials have been completed.
AL002 is a distinct investigational small molecule developed by Alector, Inc. for Alzheimer's disease. It is not known to be the same as any other marketed or investigational Alzheimer's drug. Its mechanism of action and clinical profile are being evaluated in ongoing research.